{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:58:57Z","timestamp":1761469137712,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.transci.2020.102911","type":"journal-article","created":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T11:43:12Z","timestamp":1598269392000},"page":"102911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Naso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetana","family":"Porto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Paviglianiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Loteta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Moscato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Console","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale Fabio","family":"Provenzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Lisa","family":"Pitino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Tripepi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"December 18 (9758)","key":"10.1016\/j.transci.2020.102911_bib0005","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"November 24 (22)","key":"10.1016\/j.transci.2020.102911_bib0010","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"August 30 (9)","key":"10.1016\/j.transci.2020.102911_bib0015","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"August 23 (8)","key":"10.1016\/j.transci.2020.102911_bib0020","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Programa para el Estudio y la Terap\u00e9utica de las Hemopat\u00edas Malignas\/Grupo Espa\u00f1ol de Mieloma (PETHEMA\/GEM) group","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"September 1 (25)","key":"10.1016\/j.transci.2020.102911_bib0025","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"July (7)","key":"10.1016\/j.transci.2020.102911_bib0030","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41375-019-0384-1","article-title":"Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia"},{"issue":"September 4 (10)","key":"10.1016\/j.transci.2020.102911_bib0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"December (16)","key":"10.1016\/j.transci.2020.102911_bib0040","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"September (9)","key":"10.1016\/j.transci.2020.102911_bib0045","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.bbmt.2017.05.035","article-title":"Current use and trends in hematopoietic cell transplantation in the United States","volume":"23","author":"D\u2019Souza","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"February 17","key":"10.1016\/j.transci.2020.102911_bib0050","article-title":"European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T\u2019s come into focus","author":"Passweg","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"July 6 (10192)","key":"10.1016\/j.transci.2020.102911_bib0055","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone With or Without Daratumumab Before and After Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"October 24 (5)","key":"10.1016\/j.transci.2020.102911_bib0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5500\/wjt.v7.i5.250","article-title":"Peripheral Blood Stem Cell Mobilization in Multiple Myeloma: Growth Factors or Chemotherapy?","volume":"7","author":"Wallis","year":"2017","journal-title":"World J Transplant"},{"key":"10.1016\/j.transci.2020.102911_bib0065","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.transci.2017.11.028","article-title":"Current status of art mobilization in myeloma","volume":"56","author":"Sevindik","year":"2017","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2020.102911_bib0070","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbmt.2009.02.011","article-title":"Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma","volume":"15","author":"Popat","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102911_bib0075","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ejh.12843","article-title":"Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma","volume":"98","author":"Gettys","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.transci.2020.102911_bib0080","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/bmt.2016.123","article-title":"Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma","volume":"51","author":"Green","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102911_bib0085","doi-asserted-by":"crossref","first-page":"6319","DOI":"10.4081\/hr.2016.6319","article-title":"The high effect of Chemomobilization with high-dose etopside + granulocyte-colony stimulating factor in autologous hematopoietic peripheral blood stem cell transplantation: a single center experience","volume":"8","author":"G\u00fcner","year":"2016","journal-title":"Hematol Rep"},{"issue":"64","key":"10.1016\/j.transci.2020.102911_bib0090","volume":"6","author":"Musto","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.transci.2020.102911_bib0095","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2008.04.008","article-title":"Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma","volume":"14","author":"Mark","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"January (1)","key":"10.1016\/j.transci.2020.102911_bib0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/10428194.2017.1324161","article-title":"Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma","volume":"59","author":"Milone","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2020.102911_bib0105","first-page":"4476","article-title":"Outpatient stem cell mobilization with low and intermediate dose cyclophosphamide is a safe and effective procedure in newly diagnosed multiple myeloma patients eligible for stem cell transplantation","volume":"130","author":"Pompa","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102911_bib0110","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.bbmt.2012.01.005","article-title":"Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies","volume":"18","author":"Hamadani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"October (5)","key":"10.1016\/j.transci.2020.102911_bib0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jca.21283","article-title":"Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma","volume":"28","author":"Shimura","year":"2013","journal-title":"J Clin Apher"},{"issue":"2","key":"10.1016\/j.transci.2020.102911_bib0120","first-page":"106","article-title":"Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management","volume":"25","author":"Boussios","year":"2012","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.transci.2020.102911_bib0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/annonc\/mdq600","article-title":"Update and new trends in antiemetic therapy: the continuing need for novel therapies","volume":"22","author":"Feyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.transci.2020.102911_bib0130","first-page":"89","article-title":"Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting-two new agents","volume":"1","author":"Navari","year":"2003","journal-title":"J Support Oncol"},{"issue":"September (suppl5)","key":"10.1016\/j.transci.2020.102911_bib0135","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"Participants of the MASCC\/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"issue":"October 1 (28)","key":"10.1016\/j.transci.2020.102911_bib0140","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: american society of clinical oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"year":"2020","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae). Antiemesis. Version 1","author":"NCCN (National Comprehensive Cancer Network\u00ae)","key":"10.1016\/j.transci.2020.102911_bib0145"},{"key":"10.1016\/j.transci.2020.102911_bib0150","first-page":"1609","article-title":"Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study","volume":"19","author":"Boccia","year":"2011","journal-title":"Support Care Cancer"},{"issue":"23","key":"10.1016\/j.transci.2020.102911_bib0155","first-page":"1769","article-title":"(2015) A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients","author":"Kim","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.transci.2020.102911_bib0160","first-page":"945","article-title":"Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study","volume":"24","author":"Seol","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.transci.2020.102911_bib0165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/1078155209104063","article-title":"Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting","volume":"15","author":"Howell","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.transci.2020.102911_bib0170","first-page":"19","article-title":"Results from four pharmacokinetic studies of the granisetron transdermal system","volume":"2","author":"Haislip","year":"2013","journal-title":"Res Rep Transdermal Drug Deliv"},{"key":"10.1016\/j.transci.2020.102911_bib0175","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood.V74.6.1905.1905","article-title":"Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony- stimulating factor","volume":"74","author":"Siena","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.transci.2020.102911_bib0180","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for MR. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2020.102911_bib0185","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1200\/JCO.1989.7.8.1142","article-title":"Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population","volume":"7","author":"Lindley","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.transci.2020.102911_bib0190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF00874423","article-title":"Methodological issues in antiemetic studies","volume":"11","author":"Aapro","year":"1993","journal-title":"Invest New Drugs"},{"issue":"24","key":"10.1016\/j.transci.2020.102911_bib0195","first-page":"2932","article-title":"American Society of Clinical O.nCology guideline for antiemetics in oncology: update 2006","author":"American Society of Clinical O","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.transci.2020.102911_bib0200","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.transci.2020.102911_bib0205","first-page":"1609","article-title":"Sancuso Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study","volume":"19","author":"Boccia","year":"2011","journal-title":"Support Care Cancer"},{"issue":"24","key":"10.1016\/j.transci.2020.102911_bib0210","first-page":"945","article-title":"Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study","volume":"2016","author":"Seol","year":"2016","journal-title":"Support Care Cancer"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050220302251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:53:15Z","timestamp":1761468795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050220302251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1473050220302251"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2020.102911","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2020.102911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102911"}}